HK1255108A1 - 核苷類藥物的氨基磷酸酯衍生物的製劑 - Google Patents

核苷類藥物的氨基磷酸酯衍生物的製劑

Info

Publication number
HK1255108A1
HK1255108A1 HK18114263.1A HK18114263A HK1255108A1 HK 1255108 A1 HK1255108 A1 HK 1255108A1 HK 18114263 A HK18114263 A HK 18114263A HK 1255108 A1 HK1255108 A1 HK 1255108A1
Authority
HK
Hong Kong
Prior art keywords
formulations
phosphoramidate derivatives
nucleoside drugs
nucleoside
drugs
Prior art date
Application number
HK18114263.1A
Other languages
English (en)
Inventor
Gordon Kennovin
Hugh Griffith
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of HK1255108A1 publication Critical patent/HK1255108A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK18114263.1A 2015-12-23 2018-11-08 核苷類藥物的氨基磷酸酯衍生物的製劑 HK1255108A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522764.8A GB201522764D0 (en) 2015-12-23 2015-12-23 Formulations of phosphate derivatives
PCT/GB2016/054025 WO2017109491A1 (en) 2015-12-23 2016-12-21 Formulations of phosphoramidate derivatives of nucleoside drugs

Publications (1)

Publication Number Publication Date
HK1255108A1 true HK1255108A1 (zh) 2019-08-02

Family

ID=55311533

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114263.1A HK1255108A1 (zh) 2015-12-23 2018-11-08 核苷類藥物的氨基磷酸酯衍生物的製劑

Country Status (20)

Country Link
US (3) US20180369266A1 (zh)
EP (1) EP3393453A1 (zh)
JP (2) JP6913095B2 (zh)
KR (1) KR20180091919A (zh)
CN (1) CN108697636A (zh)
AU (2) AU2016375866B2 (zh)
BR (2) BR122023000551B1 (zh)
CA (1) CA3008751C (zh)
CL (1) CL2018001672A1 (zh)
EA (2) EA202190058A1 (zh)
GB (1) GB201522764D0 (zh)
HK (1) HK1255108A1 (zh)
IL (1) IL260008A (zh)
MA (1) MA44117A (zh)
MX (2) MX2018007794A (zh)
MY (1) MY196741A (zh)
PH (1) PH12018501341A1 (zh)
SA (1) SA518391858B1 (zh)
SG (2) SG11201805318SA (zh)
WO (1) WO2017109491A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DK2681227T3 (da) 2011-03-01 2016-02-22 Nucana Biomed Ltd Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
WO2023218202A2 (en) 2022-05-12 2023-11-16 NuCana plc Cancer treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011981A (es) 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
GB0412866D0 (en) 2004-06-09 2004-07-14 Novartis Ag Organic compounds
US20090022803A1 (en) 2005-01-27 2009-01-22 Erimos Pharmaceuticals Llc Oral Formulations For Delivery of Catecholic Butanes Including Ndga Compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
KR101201956B1 (ko) 2009-03-18 2012-11-19 신동헌 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑색종의 예방 또는 치료용 약학적 조성물
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
DK2681227T3 (da) * 2011-03-01 2016-02-22 Nucana Biomed Ltd Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
WO2013070887A1 (en) 2011-11-10 2013-05-16 Inhibitex, Inc. Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
WO2013107515A1 (en) 2012-01-20 2013-07-25 Okapi Sciences Nv Eye drop composition
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
JP6855248B2 (ja) * 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
US10570168B2 (en) * 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
US20220031728A1 (en) 2022-02-03
SG10202008554RA (en) 2020-10-29
JP2021165310A (ja) 2021-10-14
EA202190058A1 (ru) 2021-06-30
AU2016375866A1 (en) 2018-07-05
SG11201805318SA (en) 2018-07-30
AU2022211797B2 (en) 2024-04-04
EP3393453A1 (en) 2018-10-31
EA037320B1 (ru) 2021-03-11
IL260008A (en) 2018-07-31
CL2018001672A1 (es) 2019-02-01
US20180369266A1 (en) 2018-12-27
AU2022211797A1 (en) 2022-08-25
JP6913095B2 (ja) 2021-08-04
JP2018538342A (ja) 2018-12-27
GB201522764D0 (en) 2016-02-03
EA201891471A1 (ru) 2018-12-28
MX2018007794A (es) 2019-07-01
MY196741A (en) 2023-05-03
BR112018012951A2 (pt) 2018-12-11
PH12018501341A1 (en) 2019-02-18
CN108697636A (zh) 2018-10-23
MA44117A (fr) 2021-03-31
SA518391858B1 (ar) 2022-10-30
BR122023000551B1 (pt) 2023-12-05
WO2017109491A1 (en) 2017-06-29
MX2021010601A (es) 2021-09-28
US11786544B2 (en) 2023-10-17
BR112018012951B1 (pt) 2023-12-12
AU2016375866B2 (en) 2022-06-09
US20240082287A1 (en) 2024-03-14
CA3008751A1 (en) 2017-06-29
KR20180091919A (ko) 2018-08-16
CA3008751C (en) 2023-10-03

Similar Documents

Publication Publication Date Title
HK1255108A1 (zh) 核苷類藥物的氨基磷酸酯衍生物的製劑
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
SG11201706729SA (en) Derivatives of sobetirome
IL263121B (en) History of nucleoside phosphoramidate as anticancer agents
PL4070788T3 (pl) Formulacje farmaceutyczne
HK1254343A1 (zh) 藥物製劑
HK1252322A1 (zh) 製備細胞毒性苯並二氮雜䓬衍生物的方法
HK1252534A1 (zh) 來氟米林的可注射藥物組合物
ZA201707094B (en) Pharmaceutical formulations
EP3506947A4 (en) PHARMACEUTICAL FORMULATIONS OF REGADENOSONE
IL267279A (en) Pharmaceutical formulations of suvorexant
GB201417646D0 (en) Formulations of phosphate derivatives